Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.63 USD | +2.52% | +0.31% | -38.26% |
May. 09 | Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 08 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 |
Business Summary
Number of employees: 53
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Injectable Biologics
100.0
%
| 1 | 100.0 % | 5 | 100.0 % | +340.88% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 5 | 100.0 % | +340.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Anish Suri
PSD | President | 50 | 18-06-30 |
Kerri-Ann Millar
DFI | Director of Finance/CFO | 54 | 17-08-31 |
Matteo Levisetti
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-21 |
Marie Campinell
IRC | Investor Relations Contact | - | - |
Colin Sandercock
LAW | General Counsel | 67 | 17-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 18-06-25 |
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Peter Kiener
BRD | Director/Board Member | 72 | 16-02-29 |
Frank Morich
CHM | Chairman | 69 | 18-08-02 |
Patrick Verheyen
BRD | Director/Board Member | 64 | 23-04-10 |
Pamela Garzone
BRD | Director/Board Member | 70 | 23-04-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 48,643,316 | 48,313,028 ( 99.32 %) | 0 | 99.32 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.26% | 79.29M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- CUE Stock
- Company Cue Biopharma, Inc.